Key Takeaways:
Protagonist Therapeutics shares jumped 64% over six months as two pipeline catalysts reshaped the company's revenue outlook.
"The restructured rusfertide agreement with Takeda provides Protagonist with more predictable income and reduces our commercial risk," the company said in an April filing.
Protagonist exited its U.S. profit-sharing agreement with Takeda for rusfertide in April, receiving a $400 million upfront payment that included a $200 million opt-out payment. The company is also eligible for a $75 million milestone upon FDA approval, up to $775 million in sales milestones and tiered royalties of 14% to 29% on global sales. The FDA accepted the new drug application for rusfertide with priority review in March and set a target action date of August 2026.
The stock rally accelerated after the FDA approved Icotyde (icotrokinra) in March for moderate-to-severe plaque psoriasis, making it the first oral targeted peptide approved for the indication. The approval triggered a $50 million milestone payment from Johnson & Johnson, with up to $580 million in additional regulatory and sales milestones plus tiered royalties of 6% to 10% on net sales.
Icotyde was co-developed by Protagonist and Johnson & Johnson under a 2017 collaboration agreement, with PTGX leading early-stage development and JNJ holding exclusive global rights for late-stage development and commercialization. The drug's approval was based on data from four Phase III studies — ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 — evaluating the therapy across psoriasis and psoriatic arthritis indications.
Unlike current effective treatments for plaque psoriasis, which are injectables such as AbbVie's Skyrizi and J&J's own Tremfya, Icotyde is a once-daily oral pill. The drug is also under review in the European Union for the same indication and is being evaluated for active psoriatic arthritis, moderate-to-severe active ulcerative colitis and Crohn's disease.
Beyond its partnered programs, Protagonist is advancing wholly owned pipeline assets. PN-881, an oral IL-17 antagonist, is expected to complete Phase I and enter Phase II in 2026. PN-477, a triple GLP/GIP/GCG agonist, is moving toward Phase I, while PN-458 and PN-8047 remain in IND-enabling studies.
The rusfertide PDUFA date in August 2026 represents the next major milestone for Protagonist, with peak sales estimates tied to its first-in-class hepcidin mimetic mechanism. Icotyde's expanding label and EU review provide additional upside beyond the psoriasis approval.
This article is for informational purposes only and does not constitute investment advice.
